Please ensure Javascript is enabled for purposes of website accessibility

Independent Monitors Suggest Shorter Timeline for Novocure's Lung Cancer Treatment

By Todd Campbell - Updated Apr 14, 2021 at 8:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A trial examining the use of Novocure's tumor-treating field technology in non-small cell lung cancer patients could enroll fewer patients over a shorter period, based on recommendations by an independent committee.

After reviewing interim results from 210 patients participating in a phase 3 study, an independent monitoring committee is recommending changes to Novocure's (NVCR 5.47%) non-small cell lung cancer (NSCLC) trial. Specifically, the committee is suggesting that the number of patients enrolled in the study be reduced to 276 patients from 534 patients and the patient follow-up period be shortened to 12 months from 18 months.

The committee said it's "likely unnecessary and possibly unethical for patients randomized to the control arm to continue accrual" to the prior enrollment target and timeline.

A woman wearing a lab coat speaks through a megaphone.


The trial is evaluating the impact of Novocure's tumor-treating fields, or TTFs, on overall survival rates. TTFs are specially tuned frequencies that can disrupt cancer cell division and multiplication in patients via a specially designed vest and external device. The primary endpoint of the study is determining if adding TTFs to checkpoint inhibitors or docetaxel -- two commonly used NSCLC treatments -- improves outcomes.

Although Novocure remains blind to the interim results from this trial, the independent-monitors' guidance suggests the data is compelling. If so, then TTFs could eventually reshape patient treatment. There are nearly 200,000 new cases of NSCLC diagnosed in the U.S. annually and unfortunately, the five-year survival rate across all lung cancers is only 20.5%, according to the National Cancer Institute.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NovoCure Stock Quote
$73.30 (5.47%) $3.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.